These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 31196609)

  • 41. Association of Glomerular Complement C4c Deposition With the Progression of Diabetic Kidney Disease in Patients With Type 2 Diabetes.
    Duan S; Sun L; Nie G; Chen J; Zhang C; Zhu H; Huang Z; Qian J; Zhao X; Xing C; Zhang B; Yuan Y
    Front Immunol; 2020; 11():2073. PubMed ID: 32983156
    [No Abstract]   [Full Text] [Related]  

  • 42. Progression of diabetic kidney disease in T2DN rats.
    Palygin O; Spires D; Levchenko V; Bohovyk R; Fedoriuk M; Klemens CA; Sykes O; Bukowy JD; Cowley AW; Lazar J; Ilatovskaya DV; Staruschenko A
    Am J Physiol Renal Physiol; 2019 Dec; 317(6):F1450-F1461. PubMed ID: 31566426
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A study of the natural history of diabetic kidney disease (DKD).
    Altemtam N; Russell J; El Nahas M
    Nephrol Dial Transplant; 2012 May; 27(5):1847-54. PubMed ID: 22058177
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mitochondrial dysfunction in diabetic kidney disease.
    Forbes JM; Thorburn DR
    Nat Rev Nephrol; 2018 May; 14(5):291-312. PubMed ID: 29456246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases.
    Huang W; Chen YY; Li ZQ; He FF; Zhang C
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142794
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oxidative stress as a culprit in diabetic kidney disease.
    Su S; Ma Z; Wu H; Xu Z; Yi H
    Life Sci; 2023 Jun; 322():121661. PubMed ID: 37028547
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Renal fibrosis as a hallmark of diabetic kidney disease: potential role of targeting transforming growth factor-beta (TGF-β) and related molecules.
    Tang J; Liu F; Cooper ME; Chai Z
    Expert Opin Ther Targets; 2022 Aug; 26(8):721-738. PubMed ID: 36217308
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hyperuricemia contributes to the faster progression of diabetic kidney disease in type 2 diabetes mellitus.
    Bartáková V; Kuricová K; Pácal L; Nová Z; Dvořáková V; Švrčková M; Malúšková D; Svobodová I; Řehořová J; Svojanovský J; Olšovský J; Bělobrádková J; Kaňková K
    J Diabetes Complications; 2016; 30(7):1300-7. PubMed ID: 27324705
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metformin and Canagliflozin Are Equally Renoprotective in Diabetic Kidney Disease but Have No Synergistic Effect.
    Corremans R; Vervaet BA; Dams G; D'Haese PC; Verhulst A
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240387
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach.
    Carlsson AC; Nowak C; Lind L; Östgren CJ; Nyström FH; Sundström J; Carrero JJ; Riserus U; Ingelsson E; Fall T; Ärnlöv J
    Ups J Med Sci; 2020 Feb; 125(1):37-43. PubMed ID: 31805809
    [No Abstract]   [Full Text] [Related]  

  • 51. Extracellular vesicles and diabetic kidney disease: a systematic review.
    Tao QR; Wang LZ; Tu C
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8978-8987. PubMed ID: 32964987
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological Targeting of Mitochondria in Diabetic Kidney Disease.
    Cleveland KH; Schnellmann RG
    Pharmacol Rev; 2023 Mar; 75(2):250-262. PubMed ID: 36781216
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mechanism of progression of diabetic kidney disease mediated by podocyte mitochondrial injury.
    Su J; Ye D; Gao C; Huang Q; Gui D
    Mol Biol Rep; 2020 Oct; 47(10):8023-8035. PubMed ID: 32918716
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gene expression profiles of diabetic kidney disease and neuropathy in eNOS knockout mice: Predictors of pathology and RAS blockade effects.
    Eid SA; Hinder LM; Zhang H; Eksi R; Nair V; Eddy S; Eichinger F; Park M; Saha J; Berthier CC; Jagadish HV; Guan Y; Pennathur S; Hur J; Kretzler M; Feldman EL; Brosius FC
    FASEB J; 2021 May; 35(5):e21467. PubMed ID: 33788970
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changing trends in end-stage renal disease due to diabetes in the United kingdom.
    Hill CJ; Fogarty DG
    J Ren Care; 2012 Feb; 38 Suppl 1():12-22. PubMed ID: 22348360
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives.
    Wang Y; Jin M; Cheng CK; Li Q
    Front Endocrinol (Lausanne); 2023; 14():1238927. PubMed ID: 37600689
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HEROIC: a 5-year observational cohort study aimed at identifying novel factors that drive diabetic kidney disease: rationale and study protocol.
    Mccafferty K; Caplin B; Knight S; Hockings P; Wheeler D; Fan SL; Hulthe J; Kleta R; Ashman N; Papastefanou V; Mehta H; Salama A; Hadzovic S; Chowdhury TA; Jarl L; Unwin R; Challis B; Sundgren AK; Yaqoob MM
    BMJ Open; 2020 Sep; 10(9):e033923. PubMed ID: 32912939
    [TBL] [Abstract][Full Text] [Related]  

  • 58. NADH/NAD
    Yan LJ
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34068842
    [TBL] [Abstract][Full Text] [Related]  

  • 59. What do we know about biomarkers in diabetic kidney disease?
    Kwiendacz H; Nabrdalik K; Stompór T; Gumprecht J
    Endokrynol Pol; 2020; 71(6):545-550. PubMed ID: 33378070
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Renal intrinsic cells remodeling in diabetic kidney disease and the regulatory effects of SGLT2 Inhibitors.
    Guo W; Li H; Li Y; Kong W
    Biomed Pharmacother; 2023 Sep; 165():115025. PubMed ID: 37385209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.